Matches in SemOpenAlex for { <https://semopenalex.org/work/W4210730602> ?p ?o ?g. }
Showing items 1 to 74 of
74
with 100 items per page.
- W4210730602 abstract "The mechanisms behind the beneficial cardiovascular effects of glucagon-like peptide-1 receptor agonists (GLP-1RAs) compared with dipeptidyl peptidase-4 inhibitors (DPP4is) remain largely unknown, despite both targeting the incretin pathway to improve glycaemic control. In these prespecified secondary analyses of the LYDIA trial, we examined the impact of the GLP-1RA liraglutide (1.8 mg once-daily) and the DPP4i sitagliptin (100 mg once-daily) on circulating cardiovascular biomarkers associated with atherosclerotic risk, including circulating progenitor cells (CPCs). LYDIA was a 26-week, randomized, active-comparator trial in 61 adults with type 2 diabetes and obesity (mean +/- SD: age 43.8 +/- 6.5 years, body mass index 35.3 +/- 6.4 kg/m(2), HbA1c 7.5% +/- 0.83% [58.5 +/- 9.1 mmol/mol]). Vascular endothelial growth factor (VEGF) and stromal cell-derived factor-1-alpha (SDF-1alpha), both of which are implicated in endothelial function, were higher at 26 weeks with liraglutide therapy compared with sitagliptin (mean between-group difference [95% CI]: 77.03 [18.29, 135.77] pg/mL, p = .010; and 996.25 [818.85, 1173.64] pg/mL, p < .001, respectively). There were no between-group differences in CPCs, nitric oxide, C-reactive protein, interleukin-6, tumour necrosis factor alpha and advanced glycation end-products. These analyses suggest a favourable impact of liraglutide on VEGF and SDF-1alpha levels compared with sitagliptin. These factors may therefore be implicated in the differential cardiovascular effects observed between these agents in large cardiovascular outcome trials. However, these are secondary analyses from a previous trial and thus hypothesis-generating. Purposive trials are required to examine these findings further." @default.
- W4210730602 created "2022-02-08" @default.
- W4210730602 creator A5002234187 @default.
- W4210730602 creator A5016151641 @default.
- W4210730602 creator A5017924749 @default.
- W4210730602 creator A5022023562 @default.
- W4210730602 creator A5025697038 @default.
- W4210730602 creator A5030285688 @default.
- W4210730602 creator A5038288835 @default.
- W4210730602 creator A5042443875 @default.
- W4210730602 creator A5045872881 @default.
- W4210730602 creator A5051363076 @default.
- W4210730602 creator A5068804442 @default.
- W4210730602 creator A5068955598 @default.
- W4210730602 date "2021-01-23" @default.
- W4210730602 modified "2023-10-16" @default.
- W4210730602 title "Author response for Effects of liraglutide versus sitagliptin on circulating cardiovascular biomarkers, including circulating progenitor cells, in individuals with type 2 diabetes and obesity: Analyses from the LYDIA trial" @default.
- W4210730602 doi "https://doi.org/10.1111/dom.14343/v2/response1" @default.
- W4210730602 hasPublicationYear "2021" @default.
- W4210730602 type Work @default.
- W4210730602 citedByCount "0" @default.
- W4210730602 crossrefType "peer-review" @default.
- W4210730602 hasAuthorship W4210730602A5002234187 @default.
- W4210730602 hasAuthorship W4210730602A5016151641 @default.
- W4210730602 hasAuthorship W4210730602A5017924749 @default.
- W4210730602 hasAuthorship W4210730602A5022023562 @default.
- W4210730602 hasAuthorship W4210730602A5025697038 @default.
- W4210730602 hasAuthorship W4210730602A5030285688 @default.
- W4210730602 hasAuthorship W4210730602A5038288835 @default.
- W4210730602 hasAuthorship W4210730602A5042443875 @default.
- W4210730602 hasAuthorship W4210730602A5045872881 @default.
- W4210730602 hasAuthorship W4210730602A5051363076 @default.
- W4210730602 hasAuthorship W4210730602A5068804442 @default.
- W4210730602 hasAuthorship W4210730602A5068955598 @default.
- W4210730602 hasConcept C126322002 @default.
- W4210730602 hasConcept C134018914 @default.
- W4210730602 hasConcept C167734588 @default.
- W4210730602 hasConcept C2776782570 @default.
- W4210730602 hasConcept C2777025900 @default.
- W4210730602 hasConcept C2777180221 @default.
- W4210730602 hasConcept C2777391703 @default.
- W4210730602 hasConcept C2779284873 @default.
- W4210730602 hasConcept C2780282729 @default.
- W4210730602 hasConcept C2781308992 @default.
- W4210730602 hasConcept C555293320 @default.
- W4210730602 hasConcept C71924100 @default.
- W4210730602 hasConceptScore W4210730602C126322002 @default.
- W4210730602 hasConceptScore W4210730602C134018914 @default.
- W4210730602 hasConceptScore W4210730602C167734588 @default.
- W4210730602 hasConceptScore W4210730602C2776782570 @default.
- W4210730602 hasConceptScore W4210730602C2777025900 @default.
- W4210730602 hasConceptScore W4210730602C2777180221 @default.
- W4210730602 hasConceptScore W4210730602C2777391703 @default.
- W4210730602 hasConceptScore W4210730602C2779284873 @default.
- W4210730602 hasConceptScore W4210730602C2780282729 @default.
- W4210730602 hasConceptScore W4210730602C2781308992 @default.
- W4210730602 hasConceptScore W4210730602C555293320 @default.
- W4210730602 hasConceptScore W4210730602C71924100 @default.
- W4210730602 hasLocation W42107306021 @default.
- W4210730602 hasOpenAccess W4210730602 @default.
- W4210730602 hasPrimaryLocation W42107306021 @default.
- W4210730602 hasRelatedWork W1233596226 @default.
- W4210730602 hasRelatedWork W1969181381 @default.
- W4210730602 hasRelatedWork W2037395799 @default.
- W4210730602 hasRelatedWork W2103969845 @default.
- W4210730602 hasRelatedWork W2125359871 @default.
- W4210730602 hasRelatedWork W2171533058 @default.
- W4210730602 hasRelatedWork W2588190452 @default.
- W4210730602 hasRelatedWork W2944172663 @default.
- W4210730602 hasRelatedWork W3030504881 @default.
- W4210730602 hasRelatedWork W4291003989 @default.
- W4210730602 isParatext "false" @default.
- W4210730602 isRetracted "false" @default.
- W4210730602 workType "peer-review" @default.